Total Payments
$151,294
2024 Payments
$9,509
Companies
58
Transactions
1,765
Medicare Patients
22,872
Medicare Billing
$4.5M
Payment Breakdown by Category
Other$104,570 (69.1%)
Food & Beverage$38,920 (25.7%)
Travel$7,070 (4.7%)
Consulting$500.00 (0.3%)
Education$234.58 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $104,570 | 45 | 69.1% |
| Food and Beverage | $38,920 | 1,635 | 25.7% |
| Travel and Lodging | $7,070 | 59 | 4.7% |
| Consulting Fee | $500.00 | 1 | 0.3% |
| Education | $234.58 | 25 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amarin Pharma Inc. | $75,203 | 224 | $0 (2022) |
| Kowa Pharmaceuticals America, Inc. | $27,832 | 83 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $11,718 | 231 | $0 (2024) |
| Amgen Inc. | $7,440 | 151 | $0 (2024) |
| Medicure Pharma Inc. | $3,298 | 6 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $2,198 | 76 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,999 | 94 | $0 (2024) |
| Novo Nordisk Inc | $1,936 | 80 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $1,586 | 55 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,340 | 39 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,509 | 179 | Amgen Inc. ($4,637) |
| 2023 | $5,187 | 170 | Bayer Healthcare Pharmaceuticals Inc. ($487.49) |
| 2022 | $4,646 | 200 | Amgen Inc. ($692.08) |
| 2021 | $4,797 | 197 | Impulse Dynamics (USA) Inc. ($816.36) |
| 2020 | $9,757 | 201 | Amarin Pharma Inc. ($6,879) |
| 2019 | $24,696 | 202 | Amarin Pharma Inc. ($18,798) |
| 2018 | $56,692 | 323 | Amarin Pharma Inc. ($28,830) |
| 2017 | $36,011 | 293 | Amarin Pharma Inc. ($20,420) |
All Payment Transactions
1,765 individual payment records from CMS Open Payments — Page 1 of 71
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $33.53 | General |
| Category: Cardiology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $25.63 | General |
| Category: Cardiovascular | ||||||
| 12/17/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $17.45 | General |
| Category: Diabetes | ||||||
| 12/17/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $14.98 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/11/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 12/06/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $20.33 | General |
| Category: Cardiology | ||||||
| 12/05/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $4.08 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/04/2024 | Edwards Lifesciences Corporation | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) (Device) | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: Transcatheter Heart Valves | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.52 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/26/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $18.47 | General |
| Category: Cardiology | ||||||
| 11/22/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $145.25 | General |
| Category: Cardio-renal | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $12.66 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/20/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $27.98 | General |
| Category: Genetic Disease | ||||||
| 11/13/2024 | Edwards Lifesciences Corporation | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) (Device) | Food and Beverage | In-kind items and services | $21.13 | General |
| Category: Transcatheter Heart Valves | ||||||
| 11/12/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $24.01 | General |
| 11/11/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $23.08 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 11/06/2024 | ShockWave Medical, Inc | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter (Device) | Food and Beverage | In-kind items and services | $203.28 | General |
| Category: Lithoplasty | ||||||
| 11/05/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $20.15 | General |
| Category: Cardiovascular | ||||||
| 11/05/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $17.18 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 11/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $27.77 | General |
| Category: DIABETES | ||||||
| 11/01/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $6.28 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/01/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $2.07 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/31/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $24.26 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/25/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: Cardio-renal | ||||||
| 10/25/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.14 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 46 | 6,433 | 18,457 | $3.1M | $1.3M |
| 2022 | 51 | 5,600 | 14,156 | $2.6M | $1.1M |
| 2021 | 48 | 5,768 | 14,558 | $2.8M | $1.2M |
| 2020 | 48 | 5,071 | 11,449 | $2.2M | $873,764 |
Total Patients
22,872
Total Services
58,620
Medicare Billing
$4.5M
Procedure Codes
197
All Medicare Procedures & Services
197 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 598 | 1,995 | $568,575 | $211,764 | 37.2% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 202 | 220 | $470,800 | $177,001 | 37.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 206 | 2,082 | $322,710 | $140,661 | 43.6% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 360 | 2,781 | $161,298 | $115,203 | 71.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 485 | 538 | $252,860 | $95,910 | 37.9% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 308 | 2,417 | $113,552 | $81,661 | 71.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 320 | 493 | $197,200 | $73,271 | 37.2% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 224 | 1,811 | $85,117 | $63,901 | 75.1% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 240 | 1,372 | $102,900 | $59,763 | 58.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 243 | 352 | $149,600 | $51,594 | 34.5% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 240 | 247 | $113,620 | $43,900 | 38.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 108 | 308 | $67,760 | $31,422 | 46.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 108 | 108 | $52,920 | $18,761 | 35.5% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 49 | 63 | $39,060 | $15,379 | 39.4% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 157 | 448 | $19,264 | $14,910 | 77.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 136 | 184 | $37,720 | $13,665 | 36.2% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 51 | 56 | $35,000 | $12,304 | 35.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 640 | 947 | $33,145 | $11,210 | 33.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 71 | 71 | $20,945 | $10,198 | 48.7% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 163 | 166 | $27,390 | $10,123 | 37.0% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 48 | 52 | $23,688 | $9,482 | 40.0% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 267 | 302 | $24,160 | $9,165 | 37.9% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 136 | 143 | $25,740 | $8,827 | 34.3% |
| 93975 | Complete ultrasound of abdomen and pelvis artery and vein blood flow | Office | 2023 | 25 | 27 | $17,280 | $6,755 | 39.1% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 99 | 125 | $16,250 | $5,969 | 36.7% |
About Dr. Raveen Arora, M.D
Dr. Raveen Arora, M.D is a Cardiovascular Disease healthcare provider based in Anaheim, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164483244.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Raveen Arora, M.D has received a total of $151,294 in payments from pharmaceutical and medical device companies, with $9,509 received in 2024. These payments were reported across 1,765 transactions from 58 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($104,570).
As a Medicare-enrolled provider, Arora has provided services to 22,872 Medicare beneficiaries, totaling 58,620 services with total Medicare billing of $4.5M. Data is available for 4 years (2020–2023), covering 197 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Anaheim, CA
- Active Since 03/29/2006
- Last Updated 02/21/2013
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1164483244
Products in Payments
- Vascepa (Drug) $75,203
- Livalo (Drug) $27,832
- ENTRESTO (Drug) $11,117
- Repatha (Biological) $7,039
- ZYPITAMAG (pitavastatin) (Drug) $3,041
- XARELTO (Drug) $1,872
- ELIQUIS (Drug) $1,576
- Kerendia (Drug) $1,553
- Ozempic (Drug) $1,481
- FARXIGA (Drug) $1,248
- Edarbi (Drug) $1,242
- JARDIANCE (Drug) $1,221
- LifeVest (Device) $878.38
- Optimizer Smart System (Device) $816.36
- NEXLETOL (Drug) $682.99
- LEQVIO (Drug) $601.16
- EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) (Device) $543.86
- AMVUTTRA (Drug) $527.06
- PRALUENT ALIROCUMAB INJECTION (Biological) $517.12
- MOUNJARO (Drug) $452.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Anaheim
Mr. Narayanaiyengar Devaraj, Md, MD
Cardiovascular Disease — Payments: $13,887
Cardiovascular Disease $13,887
David Suk, Md, MD
Cardiovascular Disease — Payments: $10,578
Cardiovascular Disease $10,578
Ameesh Parikh, M.d, M.D
Cardiovascular Disease — Payments: $5,378
Cardiovascular Disease $5,378
David Kramer, M.d, M.D
Cardiovascular Disease — Payments: $3,482
Cardiovascular Disease $3,482
Dr. Prasanna Challa, M.d, M.D
Cardiovascular Disease — Payments: $1,845
Cardiovascular Disease $1,845
Ravi Jandhyala, Md, MD
Cardiovascular Disease — Payments: $1,831
Cardiovascular Disease $1,831